Breaking News
Investing Pro 0
Cyber Monday SALE: Up to 54% OFF InvestingPro+ CLAIM OFFER
Close

Genfit (GNFT)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Genfit's earnings

Delivery Method

Status

Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
3.800 -0.030    -0.78%
25/11 - Closed. Currency in USD ( Disclaimer )
Type:  Equity
Market:  United States
  • Volume: 14,560
  • Bid/Ask: 0.000 / 0.000
  • Day's Range: 3.730 - 3.870
Genfit 3.800 -0.030 -0.78%

Genfit SA Company Profile

 
Get an in-depth profile of Genfit, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryBiotechnology
SectorHealthcare
Employees

134

Equity Type

ORD

Genfit S.A., a biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company’s products include Elafibranor, which is in Phase 3 clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; GNS561, which is in Phase 1b/2 trial to treat patients with cholangiocarcinoma (CCA); and Nitazoxanide, which is in Phase 1 trial to treat acute-on-chronic liver failure. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and with Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. Genfit S.A. was incorporated in 1999 and is headquartered in Loos, France.

Contact Information

Phone 33 3 20 16 40 00
Fax 33 2 20 16 40 01

Top Executives

Name Age Since Title
Arun J. Sanyal - - Member of Scientific Advisory Board
Vlad Ratziu - - Member of Scientific Advisory Board
Katherine Bach Kalin 58 2020 Independent Director
Michael Trauner - - Member of Scientific Advisory Board
Frederic Desdouits 53 2014 Independent Director
Jean-Francois Tine 64 2021 Independent Director
Scott L. Friedman - - Member of Scientific Advisory Board
Eric Baclet 61 2020 Independent Director
Xavier Guille des Buttes 79 2006 Independent Vice-Chairman of the Board
Jean-Francois Mouney 66 1999 Co-Founder & Chairman of the Board
Bart Staels 58 - Co-Founder & Chairman of the Scientific Advisory Board
Catherine Larue 66 2011 Independent Director
Florence Séjourné 51 1999 Director
Philippe Moons 71 2015 Board Observer
Anne-Helene Monsellato 54 2017 Independent Director
Steven Hildemann 59 2022 Director
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

GNFT Comments

Write your thoughts about Genfit SA
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Aynaz Rostami
Aynaz Rostami Feb 11, 2021 9:57AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
what's the reason of fall of Genfit?
ziqing liew
ziqing liew Feb 11, 2021 9:57AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
i also want to know
Aynaz Rostami
Aynaz Rostami Feb 11, 2021 9:57AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
dont worry it Will raise soon
Thao Bui
Thao Bui Jun 26, 2020 4:57AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
it cheap to buy
CAC Invest
CAC Invest Jun 09, 2020 5:39AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Trials for NASH will continue after dataset correction
Thms Koprnk
Koprnk Jun 04, 2020 6:57AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
they failed the drug test and NASH drug was the only viable drug that they were developing , so practically they lost almost all value with that failure...
CAC Invest
CAC Invest Jun 04, 2020 6:57AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
not all value but a drug development. they have so many programs to continue
Danny Danny
Danny Danny May 21, 2020 1:03PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
damn what was wrong w this beast? from 2x all the way down to 5 w low volume?
Rajaie Issaid
Rajaie Issaid May 20, 2020 4:15PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Whats the status , will it still go down ?
Malek Brahmi
Malek Brahmi May 20, 2020 4:15PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Yes
stats con chris
stats con chris May 19, 2020 2:27PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
this baby Is the brother of contravirpharma (HEPA) .. same diseases.
MfB Iod
MfB Iod May 19, 2020 2:27PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
what do you mean?
Nedal Aysheh
Nedal Aysheh May 12, 2020 5:53PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
WHAT IS THE BEST STOCK TO BUY TODAY ??/ ANT RECOMMENDATION
MfB Iod
MfB Iod Mar 27, 2019 12:56PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
does anyone have an explaination for the sudden fall same day of the Nasdaq trading?
Show previous replies (5)
Mathieu Gandrille
Mathieu Gandrille Mar 27, 2019 12:56PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
MfB Iod  possible. today it will open low, in a range between 5 to 8. (my guess only - dyor)
Mathieu Gandrille
Mathieu Gandrille Mar 27, 2019 12:56PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
MfB Iod   i changed my recommendation to SELL, with objective at 8.0
MfB Iod
MfB Iod Mar 27, 2019 12:56PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Mathieu Gandrille  ah you mean to buy because it would be oversold
Mathieu Gandrille
Mathieu Gandrille Mar 27, 2019 12:56PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
MfB Iod   i mean if 5 i would buy, and sell at 8
Olivier Bclr
Olivier Bclr Mar 27, 2019 12:56PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Mathieu Gandrille  are you a KOL?
P SH
P SH Nov 30, 2018 10:22AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
DATA is opn in 1Q 2019?
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email